Mats Junek
@MatsJunek
Followers
517
Following
5K
Media
76
Statuses
2K
Canstralian MD MSc (HRM) // Rheumatologist & Vasculitis fellow @mcmasterU // Clinician Investigator Program 2022 - 2026 // PhD candidate 2023-202? @HEI_mcmaster
Ontario, Canada
Joined May 2014
NEW RESEARCH—In a retrospective cohort study, frailty—an approximation of biological age—was a risk factor for severe infection in older adults with ANCA-associated #vasculitis
https://t.co/TKNRzHswDv
@SattuiSEMD @zach_wallace_md
2
11
37
22nd International Vasculitis Workshop, Melbourne 2026 The biggest and definitive biannual meeting of the #Vasculitis Research, Clinical and Patient Community Go to https://t.co/vm7b0TFlI5 to register your interest. More to follow. See you in Melbourne in the southern summer!
4
20
31
If you missed our May webinary "Tools for Improving the Diagnosis of GCA" with Dr. JP Makhzoum, DR. Junek and Dr. Seidman, no problem! You can view it (along with our other webinars) online now on the CanVasc Website:
canvasc.ca
Webinars & Presentations CanVasc webinars and presentations Here are some of the webinars held by CanVasc and a few presentations given by CanVasc members during past meetings (sometimes modified and...
2
4
6
Thrilled to see @ihpmeuoft #ClinEpi student @TeresaSemalulu present her research at @UofTRheum #Ogryzlo research day! @ZahiTouma @SchroederInst
0
4
25
Congratulations to HEI student @ArnavAgarwalMD who received the 2024 Vanier Canada Graduate Scholarship! Arnav is completing his PhD in Health Research Methodology under supervisor @GuyattGH, HEI Professor. 🔗 Learn more about his research: https://t.co/N31Ld4dqD9
@machealthsci
1
5
31
I have to say: upadacitinib looks very decent for GCA. Not a panacea, but it definitely does something & good safety during trial. Would love to eventually see: - H2H comparative effect vs toci, secukinumab - structural outcomes - long-term safety #EULAR2024 PBA0001 @RheumNow
Was a full room #EULAR2024 for the SELECT-GCA presentation (upadacitinib in GCA positive study). Palpable excitement through the audience here in Vienna @RheumNow
6
17
44
#Editor’s #Choice
@MatsJunek Who #relapses in #ANCA #vasculitis In #Pexivas trial #Renal #failure may be protective from relapses. Seems to be the case in renal #lupus #GN too~my opinion ?Why 🤷 #EULAR2024 #EULARBEST @ARD_BMJ
@RheumNow @eular_org @ACR_Journals
6
15
44
📢Save the date for the upcoming @can_vasc webinar on the topic of Tools for Improving the Diagnosis of GCA, presented by Dr. Makhzoum, @MatsJunek, and @MSeidmanMD Registration opening soon!
0
1
1
We would love you to join us for the next Vasculitis Workshop. Hosted by @anzvasc. Co-convenors @KitchingLab @VickiQuincey and yours truly. Please DM if you have great ideas for us to incorporate into the next workshop #vasculitis
1
14
46
post hoc of the PEXIVAS study 704 participants w/ severe ANCA vasculitis: 92% achieved remission & 23% had relapses (rate 10.3/100PYs)-- Neither plasma exchange nor glucocorticoid tapering regimen impacted relapse risk. https://t.co/UN6RujwZKc
0
5
16
We're delighted to publish the first articles in our new 'Current and future advances in practice' series. Brain child of the fab @drdavidliew, this series aims to provide practical reviews of topics typically underrepresented by the literature ✨ 🧵 https://t.co/2zsifyYzlp
3
12
35
#ACR23 Plenary Abs #1584: TMP-SMX PPx associated w/ subsequent reduced serious and overall infections in RTX-treated GPA. Now to understand what is optimization of PPx for these pts. https://t.co/O8WE1pslzC
@rheumnow
0
2
5
Thrilled to share our new editorial co-authored with my amazing mentors @EBRheum and @MatsJunek! We discuss the limitations of the ADVOCATE trial and the importance of using modern standards of care in rheumatology trials. Read more here:
academic.oup.com
The ADVOCATE trial, which compared the novel C5a inhibitor avacopan with placebo for patients with ANCA-associated vasculitis (AAV), was an important step
3
3
18
Some thoughts on the ADVOCATE trial, great time working with @MatsJunek & @sharanyakaushik on this project. Already used the excellent diagram Sharanya put together in a talk!
Thrilled to share our new editorial co-authored with my amazing mentors @EBRheum and @MatsJunek! We discuss the limitations of the ADVOCATE trial and the importance of using modern standards of care in rheumatology trials. Read more here:
0
4
10
Attention CanVasc members: Please complete this survey to help us understand granulomas in ANCA associated vasculitis -
0
3
6
The 21st International Vasculitis Workshop will take place in Barcelona! April 7-10th, 2024 Save the date‼️😉 https://t.co/vjl9nXhxOD
2
48
106
Ocular manifestations are common in AAV, especially GPA according to this retrospective study published by our very own CanVasc members. Check it out:
0
2
3
I am thrilled to announce that I have accepted the position of the founding Dean at the brand-new Toronto Metropolitan University (TMU - @TorontoMet) School of Medicine! Official announcement here: https://t.co/43z7hjKGzy
#TMUSoM #MedEd #MedSchoolOfTheFuture
259
131
2K
#MyositisPearl 9: Have you seen a patient with increase in CK but nothing wrong with the patient. It’s called Asymptomatic HyperCKemia. Most patients don’t need beyond basic work up & most are Not #Myositis. This week I will address how to manage such patients.
15
82
249